A step towards personalizing next line therapy for resected pancreatic and related cancer patients: A single institution's experience.

ABSTRACT:

Background

There is a lack of precision medicine in pancreatic ductal adenocarcinoma (PDA) and related cancers, and outcomes for patients with this diagnosis remain poor despite decades of research investigating this disease. Therefore, it is necessary to explore novel therapeutic options for these patients who may benefit from personalized therapies.

Objective

Molecular profiling of hepatopancreaticobiliary malignancies at our institution, including but not limited to PDA, was initiated to assess the feasibility of incorporating molecular profiling results into patient oncological therapy planning.

Methods

All eligible patients from Thomas Jefferson University (TJU) with hepatopancreaticobiliary tumors including PDA, who agreed to molecular testing profiling, were pr

SUBMITTER: Lowder CY 

PROVIDER: S-EPMC7498307 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature